Cargando…

The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic

Phenotypic heterogeneity of human carcinoma lesions, including heterogeneity in expression of tumor-associated antigens (TAAs), is a well-established phenomenon. Carcinoembryonic antigen (CEA), MUC1, and brachyury are diverse TAAs, each of which is expressed on a wide range of human tumors. We have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gabitzsch, Elizabeth S., Tsang, Kwong Yok, Palena, Claudia, David, Justin M., Fantini, Massimo, Kwilas, Anna, Rice, Adrian E., Latchman, Yvette, Hodge, James W., Gulley, James L., Madan, Ravi A., Heery, Christopher R., Balint, Joseph P., Jones, Frank R., Schlom, Jeffrey
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741610/ https://www.ncbi.nlm.nih.gov/pubmed/26374823

Ejemplares similares

The generation and analysis of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic
por: Tsang, Kwong Y, et al.
Publicado: (2015)

Evaluation of immune cell subsets of cancer patients treated with Avelumab, a fully human IgG1 anti-PD-L1 MAb capable of mediating ADCC of human tumor cells
por: Lepone, Lauren, et al.
Publicado: (2015)

The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
por: Jochems, Caroline, et al.
Publicado: (2016)

An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression
por: Rice, Adrian E, et al.
Publicado: (2015)

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody
por: Donahue, Renee N., et al.
Publicado: (2017)

Impact of androgen deprivation therapy on the thymus and the production of naïve T-cells
por: Madan, Ravi A, et al.
Publicado: (2013)

Investigation of antibody dependent cellular cytotoxicity as a mechanism of action for a novel anti-PD-L1 monoclonal antibody
por: Boyerinas, Benjamin, et al.
Publicado: (2014)

Flow-cytometry phenotypic assessment of immune cell subsets reflecting function for the identification of breast cancer patients receiving vaccine plus docetaxel with longer progression-free survival
por: Grenga, Italia, et al.
Publicado: (2013)

Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
por: Madan, Ravi A, et al.
Publicado: (2012)

Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
por: Madan, Ravi A, et al.
Publicado: (2014)

Identification and characterization of agonist epitopes of the MUC1-C oncoprotein
por: Jochems, Caroline, et al.
Publicado: (2013)

Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab
por: Fujii, Rika, et al.
Publicado: (2016)

Impact of age on antigen-specific T lymphocyte response in patients treated with PSA-TRICOM
por: Singh, Harpreet, et al.
Publicado: (2014)

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
por: Gatti‐Mays, Margaret E., et al.
Publicado: (2019)

Digital immunohistochemistry analysis of intratumoral immune infiltrates in prostate cancer patients treated with intraprostatic/systemic PSA-TRICOM vaccine
por: Farsaci, Benedetto, et al.
Publicado: (2013)

Effect of age and cancer on peripheral immune cell subsets and their PD-1 and PD-L1 expression
por: Grenga, Italia, et al.
Publicado: (2015)

PD-1 and PD-L1 expression on PBMC subsets in normal individuals and cancer patients
por: Lepone, Lauren, et al.
Publicado: (2014)

Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies
por: Dominguez, Charli, et al.
Publicado: (2016)

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
por: Bilusic, Marijo, et al.
Publicado: (2019)

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death
por: Smith, Andressa A, et al.
Publicado: (2013)

Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301)
por: Donahue, Renee N, et al.
Publicado: (2014)

Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types
por: Lepone, Lauren M., et al.
Publicado: (2016)

Treatment with the IDO inhibitor INCB024360 increased lysis of human tumor cell targets by peptide-specific CTL
por: Jochems, Caroline, et al.
Publicado: (2015)

Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer
por: Burotto, Mauricio, et al.
Publicado: (2014)

Immunologic Monitoring of Cellular Immune Responses in Cancer Vaccine Therapy
por: Whiteside, Theresa L., et al.
Publicado: (2011)

Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies
por: Lopez, Diana C., et al.
Publicado: (2022)

Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer
por: Tucker, Jo A., et al.
Publicado: (2012)

A poxviral-based cancer vaccine targeting the transcription factor Twist inhibits primary tumor growth and metastases in a model of metastatic breast cancer and improves survival in a spontaneous prostate cancer model
por: Kwilas, Anna R., et al.
Publicado: (2015)

Novel adenoviral serotype 5 based immunotherapeutic induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patients
por: Morse, Michael, et al.
Publicado: (2013)

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
por: Heery, Christopher R, et al.
Publicado: (2015)

Detection and Characterization of Circulating Tumour Cells from Frozen Peripheral Blood Mononuclear Cells
por: Lu, David, et al.
Publicado: (2015)

High levels of expression of the transcription factor Brachyury induce resistance of human carcinoma cells to immune-mediated attack
por: Hamilton, Duane H, et al.
Publicado: (2013)

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells
por: David, Justin M., et al.
Publicado: (2017)

Immunological targeting of tumor cells undergoing an epithelial-mesenchymal transition via a recombinant brachyury-yeast vaccine
por: Hamilton, Duane H., et al.
Publicado: (2013)

IL15N72D superagonist/IL15Rα-Fc fusion complex (ALT-803) exhibits anti-metastatic activity in murine breast tumor model
por: Kim, Peter S, et al.
Publicado: (2015)

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele
por: Jochems, Caroline, et al.
Publicado: (2016)

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
por: Lind, Hanne, et al.
Publicado: (2020)

Immunotherapeutic intervention with oncolytic adenovirus in mouse mammary tumors
por: Gibson, Heather, et al.
Publicado: (2015)

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
por: Bilusic, Marijo, et al.
Publicado: (2021)

ABO blood type correlates with survival on prostate cancer vaccine therapy
por: Muthana, Saddam M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_h2cp2jlmrcde72fabhdvhu2r10